A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Auxilius Pharma Announces Top-line Results of its First-in-Human Clinical Study into the Pharmacokinetics, Safety and Tolerability of Antianginal AUX-001


Auxilius Pharma announces the successful conclusion of the first-in-human clinical trial of its product-in-development, AUX-001, for the treatment of chronic stable angina pectoris (NCT06249581). The trial, an exploratory Phase 1a pharmacokinetics study enlisting 16 healthy adult volunteers, was conducted in Portugal, with the clinical phase concluding just before the end of 2023.


The study investigated the pharmacokinetics of AUX-001, an oral, extended-release, once-daily version of nicorandil under fasting and fed nutritional states. The secondary objective was to assess the safety and tolerability of Auxilius’ investigational anti-anginal medication.

Topline Results

The study’s topline results showed that AUX-001 effectively extended the half-life of nicorandil from the standard 49±8 min, as seen with the current immediate-release form administered twice daily, to over 9 hours. Other pharmacokinetic parameters fall within the range indicative of an extended-release formulation. “A result like this bodes well for AUX-001’s potential to extend daylong coverage of its anti-ischemic effect with just one capsule a day,” commented Dawid Chabowski, PhD, a pharmacologist and the Science and Operational Manager at Auxilius Pharma.

Safe and Well Tolerated by Study Participants

Overall, AUX-001 was safe and well-tolerated by study participants. Headaches, a common and often transitory side effect of vasodilator medications — one of nicorandil’s two mechanisms of action — were the most common adverse events (AEs) and were proactively managed by using over the counter NSAID headache remedies, predominantly acetaminophen (paracetamol). Other AEs included asymptomatic hypotension, nasal congestion, and palpitations; however, most were mild, and none were serious, aligning with the known side effects of the active compound. Said Auxilius CMO Uwe Tigör, MD: “Headaches upon treatment initiation with nicorandil can lead 15 to 30% of patients to leave any trial. Ours is probably one of very few angina studies using oral nicorandil with no headache related patient dropouts, thanks to our preemptive management and proactive patient communication”. Nicorandil usually causes lower rates of initial headaches compared to the other vasodilator class of anti-angina medication, long-acting nitrates (LANs), which are very frequently used in the US and Europe in chronic angina patients.

Auxilius Pharma CEO Jed Litwiniuk

Auxilius Pharma considers the collective results of this clinical trial with its lead R&D product a very encouraging first step in the clinical development process. The company is actively looking toward the future and the opportunities for growth that lie ahead. Said Litwiniuk: “We are reassured by the outcomes of the trial. With our IND filing for AUX-001 planned for later this year, we are now actively opening our partnering window to seek a mid- to large-size pharmaceutical partner company to finalize the clinical development of our lead asset AUX-001.”

Intro to the US Market

The company is set to introduce AUX-001, an innovative, proprietary, once-daily formulation of Nicorandil, to the US market. This initiative follows a collaborative agreement with the FDA on the 505(b)2 regulatory pathway, capitalizing on the extensive historical data from the immediate-release version long used in Europe and Asia. As AUX-001 is anticipated to enter the US as a new chemical entity (NCE), it stands to gain up to five years of market exclusivity upon approval, further supported by Auxilius’s comprehensive intellectual property rights being secured in the US and globally. This strategic move not only underscores Auxilius Pharma’s commitment to enhancing cardiac care but also positions AUX-001 to significantly impact the treatment landscape for chronic angina in the United States.

About Chronic Stable Angina

Chronic Stable Angina Pectoris (CSAP) is one of the most common cardiovascular conditions affecting over 11 million patients in the US. It is a common manifestation of atherosclerotic coronary artery disease (CAD), marked by chest pain or discomfort due to reduced myocardial blood flow, usually triggered by physical exertion, emotional stress, or other factors. CSAP prevalence is significant and growing, with around 650.000 new cases annually in the US. Standard of care for most patients with stable coronary artery disease underlying their chronic angina optimized medical therapy with anti-anginal medications. In the US, CSAP patients suffering either daily or weekly angina symptoms are treated with at least 2 antianginal medications to control their symptoms. Despite the availability of various anti-anginal medications, there has been a considerable paucity of developing new, innovative anti-angina medications since the last anti-anginal drug launched in the US in 2006.


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy